Regulated information
Waregem (Belgium)/Rotterdam (Netherlands)[1], 9 April 2015
Excellent start of the year for Fagron
Turnover increases 29.8% to € 117.8 million
Strong organic turnover growth of 16.8%
In the first quarter of 2015, the consolidated turnover of Fagron increases by 29.8% (22.5% at constant exchange rates) to 117.8 million euros. Organic turnover growth is 16.8% (10.2% at constant exchange rates).
Turnover (x 1,000 euros) Q1 2015 Q1 2014 Total growth Total growth CER Organic growth Organic growth CER Fagron 114,952 88,274 30.2% 23.1% 16.8% 10.5% HL Technology 2,848 2,494 14.2% 0.1% 14.2% 0.1% Total 117,800 90,768 29.8% 22.5% 16.8% 10.2%CER = constant exchange rates
Ger van Jeveren, CEO of Fagron: “Fagron had an excellent start of the year with turnover growth of 29.8% and organic turnover growth of 16.8%. As a result of the continuous strategic focus on optimising and innovating pharmaceutical compounding, turnover increased in every segment of our business model: Fagron Compounding Services, Fagron Trademarks and Fagron Compounding Essentials. Fagron’s strong organic growth is primarily driven by increased volumes in Fagron Compounding Services, for both sterile and non-sterile compounding. In June 2015, the new Fagron Antibiotics compounding facility in the Netherlands will be operational. This facility will compound very specific medication for intravenous treatments and profylaxis, based on cephalosporins and beta-lactam antibiotics, at the request of hospitals, clinics, homecare and healthcare centers. Turnover growth in Fagron Trademarks is the result of the successful launch of new concepts, vehicles and formulations. These will enable prescribers and pharmacists even better to provide their patients with tailor-made pharmaceutical care. In 2015, Fagron will further strengthen its position as global market leader through an active buy-and-build strategy and robust organic growth. We are very confident about the future, sustained by a strong and extensive R&D-pipeline of innovations to optimise pharmaceutical compounding. We confirm our outlook for 2015 and expect to realise a turnover of at least 500 million euros[2] with a REBITDA[3]-margin of 26%.”
[1] This press release was sent out by Fagron NV and Fagron BV.
[2] Based on constant exchange rates (euro/US dollar of 1.250 and euro/Brazilian real of 3.100).
[3] EBITDA before non-recurrent result.
Please open the link below for the press release: